Cell Line Used to Produce Sarclisa's Antibody
Sarclisa, also known as isatuximab, is a monoclonal antibody used in the treatment of multiple myeloma and lymphoplasmacytic lymphoma. The antibody is produced through a human-mouse chimeric antibody technology, which involves combining human and mouse antibody sequences.
According to the manufacturer of Sarclisa, Sanofi, the antibody is produced in a mouse-human chimeric cell line, which is a genetically engineered cell line that combines mouse antibody variable regions with human antibody constant regions. This approach allows for the production of antibodies that have the desired binding properties while minimizing the risk of immune responses in humans.
The development of Sarclisa involved the use of a proprietary mouse-human chimeric expression system, which was designed to express the antibody heavy and light chain genes in a human-mouse chimeric cell line [1]. This technology enables the production of high-quality antibodies with optimized binding properties and stability.
While specific details about the cell line used to produce Sarclisa are not publicly available, the manufacturer has disclosed that the antibody is produced through a recombinant expression system that utilizes mammalian cell culture. The use of a mouse-human chimeric cell line allows for the efficient production of antibodies with the desired binding properties, which is critical for the development of effective therapeutic agents like Sarclisa.
To learn more about the production of Sarclisa and other biologic therapies, visit DrugPatentWatch.com [2].
Sources:
[1] Sanofi. (2020). Isatuximab Prescribing Information.
[2] DrugPatentWatch.com. (n.d.). Isatuximab (Sarclisa) Patents.